Species differences in hydrolase activities toward OT-7100 responsible for different bioavailability in rats, dogs, monkeys and humans

Xenobiotica

Volumn 36, Issue 4, 2006, Pages 301-314

  Kuribayashi, S ^a,b   Ueda, N ^b   Naito, S ^b   Yamazaki, H ^a   Kamataki, T ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Bioavailability; Hydrolysis; Pyrazolopyrimidine derivative; Small intestine; Species differences

Indexed keywords

5 BUTYL 7 (3,4,5 TRIMETHOXYBENZAMIDO)PYRAZOLO[1,5 A]PYRIMIDINE; 5 N BUTYL 7 (3,4,5 TRIMETHOXYBENZOYLAMINO)PYRAZOLO[1,5 A]PYRIMIDINE; CELL ENZYME; CYTOPLASM ENZYME; DRUG METABOLITE; HYDROLASE; MICROSOME ENZYME; PYRAZOLOPYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION TIME PROFILE; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; ENZYME ACTIVITY; FIRST PASS EFFECT; HUMAN; LIVER; MALE; MONKEY; NONHUMAN; RAT; SMALL INTESTINE; SPECIES DIFFERENCE; TIME;

ANIMALS; CYTOSOL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HAPLORHINI; HUMANS; HYDROLASES; HYDROLYSIS; MALE; MICROSOMES, LIVER; PYRAZOLES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; SUBCELLULAR FRACTIONS;

ANIMALIA; CANIS FAMILIARIS;

EID: 33646761295     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250600571798     Document Type: Article

References (29)

1. Boogaard PJ, Van Elburg PA, De Kloe KP, Watson WP, Van Sittert NJ. 1999. Metabolic inactivation of 2-oxiranylmethyl 2-ethyl-2,5-dimethylhexanoate (C10GE) in skin, lung and liver of human, rat and mouse. Xenobiotica 29:987-1006.
2. Boxenbaum H. 1980. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: Extrapolation of data to benzodiazepines and phenytoin. Journal of Pharmacokinetics and Biopharmaceutics 8:165-176.
3. Campbell CJ, Chantrell LJ, Eastmond R. 1987. Purification and partial characterization of rat intestinal cefuroxime axetil esterase. Biochemical Pharmacology 36:2317-2324.
4. Cook CS, Karabatsos PJ, Schoenhard GL, Karim A. 1995. Species dependent esterase activities for hydrolysis of an anti-HIV prodrug glycovir and bioavailability of active SC-48334. Pharmaceutical Research 12:1158-1164.
5. Fitzsimmons ML, Collins JM. 1997. Selective biotransformation of the human immunodeficiency virus protease inhibitor Saquinavir by human small-intestinal cytochrome P4503A4. Potential contribution to high first-pass metabolism. Drug Metabolism and Disposition 25:256-266.
6. Hashizume T, Imaoka S, Mise M, Terauchi Y, Fujii T, Miyazaki H, Kamataki T, Funae Y. 2001. Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. Journal Pharmacology and Experimental Therapeutics 300:298-304.
7. Hosokawa M, Endo T, Fujisawa M, Hara S, Iwata N, Sato Y, Satoh T. 1995. Interindividual variation in carboxylesterase levels in human liver microsomes. Drug Metabolism and Disposition 23:1022-1027.
8. Hosokawa M, Maki T, Satoh T. 1990. Characterization of molecular species of liver microsomal carboxylesterases of several animal species and humans. Archives of Biochemistry and Biophysics 277:219-227.
9. Hosokawa M, Suzuki K, Takahashi D, Mori M, Satoh T, Chiba K. 2001. Purification, molecular cloning, and functional expression of dog liver microsomal acyl-CoA hydrolase: A member of the carboxylesterase multigene family. Archives of Biochemistry and Biophysics 389:245-253.
10. Imai T, Yoshigae Y, Hosokawa M, Chiba K, Otagiri M. 2003. Evidence for the involvement of a pulmonary first-pass effect via carboxylesterase in the disposition of a propranolol ester derivative after intravenous administration. Journal of Pharmacology and Experimental Therapeutics 307:1234-1242.
11. Inaba M, Ohnishi Y, Ishii H, Tanioka Y, Yoshida Y, Sudoh K, Hakusui H, Mizuno N, Ito K, Sugiyama Y. 1998. Pharmacokinetics of CPT-11 in rhesus monkeys. Cancer Chemotherapy and Pharmacology 41:103-108.
12. Inoue M, Morikawa M, Tsuboi M, Sugiura M. 1979. Species difference and characterization of intestinal esterase on the hydrolyzing activity of ester-type drugs. Japanese Journal of Pharmacology 29:9-16.
13. Lin JH. 1995. Species similarities and differences in pharmacokinetics. Drug Metabolism and Disposition 23:1008-1021.
14. Lin JH, Chiba M, Baillie TA. 1999. Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacological Reviews 51:135-158.
15. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry 193:264-275.
16. Miki S, Yoshinaga N, Iwamoto T, Yasuda T, Sato S. 2001. Antinociceptive effect of the novel compound OT-7100 in a diabetic neuropathy model. European Journal of Pharmacology 430:229-234.
17. Morgan EW, Yan B, Greenway D, Parkinson A. 1994a. Regulation of two rat liver microsomal carboxylesterase isozymes: Species differences, tissue distribution, and the effects of age, sex, and xenobiotic treatment of rats. Archives of Biochemistry and Biophysics 315:513-526.
18. Morgan EW, Yan B, Greenway D, Peterson DR, Parkinson A. 1994b. Purification and characterization of two rat liver microsomal carboxylesterases (hydrolase A and B). Archives of Biochemistry and Biophysics 31:495-512.
19. Satoh T. 1987, Role of carboxylesterases in xenobiotic metabolism. In: Bend JR, Hodgson E, Philpot RM, editors. New York, NY: Elsevier. pp 155-181.
20. Satoh T, Hosokawa M. 1998. The mammalian carboxylesterases: From molecules to functions. Annual Review of Pharmacology and Toxicology 38:257-288.
21. Thummel KE, Kunze KL, Shen DD. 1997. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Advanced Drug Delivery Reviews 27:99-127.
22. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR. 1996. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clinical Pharmacology and Therapeutics 59:491-502.
23. Yamaoka K, Nakagawa T, Uno T. 1978. Statistical moments in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 6:547-558.
24. Yan B, Matoney L, Yang D. 1999. Human carboxylesterases in term placentae: Enzymatic characterization, molecular cloning and evidence for the existence of multiple forms. Placenta 20:599-607.
25. Yasuda T, Iwamoto T, Ohara M, Sato S, Kohri H, Noguchi K, Senba E. 1999. The novel analgesic compound OT-7100 (5-nButyl-7-(3,4,5,-trimethoxybenzoylamino) pyrazolo[1,5-a]pyrimidine) attenuates mechanical nociceptive responses in animal models of acute and peripheral neuropathic hyperalgesia. Japanese Journal of Pharmacology 79:65-73.
26. Yasuda T, Okamoto K, Iwamoto T, Miki S, Yoshinaga N, Sato S, Noguchi K, Senba E. 2001. A novel analgesic compound OT-7100 attenuates nociceptive responses in animal models of inflammatory and neuropathic hyperalgesia: A possible involvement of adenosinergic anti-nociception. Japanese Journal of Pharmacology 87:214-225.
27. Zhang QY, Dunbar D, Ostrowska A, Zeisloft S, Yang J, Kaminsky LS. 1999. Characterization of human small intestinal cytochromes P-450. Drug Metabolism and Disposition 27:804-809.
28. Zhang W, Xu G, McLeod HL. 2002. Comprehensive evaluation of carboxylesterase-2 expression in normal human tissues using tissue array analysis. Applied Immunohistochemistry and Molecular Morphology 10:374-380.
29. Zhu W, Song L, Zhang H, Matoney L, Lecluyse E, Yan B. 2000. Dexamethasone differentially regulates expression of carboxylesterase genes in humans and rats. Drug Metabolism and Disposition 28:186-191.